Combination therapy with interferon alfa-2a and interleukin-2 for the treatment of metastatic cancer.

Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic Cancer

1985 • 2,616 citations

Constant-Infusion Recombinant Interleukin-2 in Adoptive Immunotherapy of Advanced Cancer

1987 • 1,224 citations

Treatment of 283 Consecutive Patients With Metastatic Melanoma or Renal Cell Cancer Using High-Dose Bolus Interleukin 2

1994 • 1,070 citations

Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2.

1985 • 737 citations

In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2.

1985 • 600 citations

High-Dose Recombinant Interleukin 2 in the Treatment of Patients With Disseminated Cancer

1986 • 459 citations

Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer.

1989 • 383 citations

In vivo administration of purified human interleukin 2. I. Half-life and immunologic effects of the Jurkat cell line-derived interleukin 2.

1985 • 368 citations

Home therapy with recombinant interleukin-2 and interferon-$alpha;2b in advanced human malignancies

1990 • 296 citations

Randomized phase II trial of high-dose interleukin-2 either alone or in combination with interferon alfa-2b in advanced renal cell carcinoma.

1993 • 211 citations

Interleukin-2 therapy in patients with metastatic malignant melanoma: a phase II study.

1990 • 206 citations

Randomized phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon alfa-2a in patients with advanced melanoma.

1993 • 181 citations

Synergistic antitumor effects of combination immunotherapy with recombinant interleukin-2 and a recombinant hybrid alpha-interferon in the treatment of established murine hepatic metastases.

1988 • 153 citations

Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three district histological types.

1986 • 149 citations

In vivo anti‐tumor activity of combinations of interferon alpha and interleukin‐2 in a murine model. Correlation of efficacy with the induction of cytotoxic cells resembling natural killer cells

1987 • 146 citations

In vivo antitumor activity of multiple injections of recombinant interleukin 2, alone and in combination with three different types of recombinant interferon, on various syngeneic murine tumors.

1988 • 131 citations

Combination Immunotherapy for Cancer:Synergistic Antitumor Interactions of Interleukin-2, Alfa Interferon, and Tumor-Infiltrating Lymphocytes

1988 • 128 citations

Immunotherapy of murine sarcomas using lymphokine activated killer cells: optimization of the schedule and route of administration of recombinant interleukin-2.

1986 • 107 citations

A prospective randomized trial evaluating prophylactic antibiotics to prevent triple-lumen catheter-related sepsis in patients treated with immunotherapy.

1990 • 105 citations

Systemic administration of interleukin-2 in humans.

1984 • 78 citations

Phase II Study of Intravenous Bolus Recombinant Interleukin-2 in Advanced Malignant Melanoma: Southwest Oncology Group Study

1991 • 52 citations

Daily alternating administration of high-dose alpha-2b-interferon and interleukin-2 bolus infusion in metastatic renal cell cancer. A phase II study

1993 • 43 citations

Phase I trial of high-dose bolus interleukin-2 and interferon alfa-2a in patients with metastatic malignancy.

1992 • 42 citations

A phase I study of recombinant human interleukin-2 and alpha-interferon-2a in patients with renal cell cancer, colorectal cancer, and malignant melanoma

1990 • 42 citations

Combination biotherapy utilizing interleukin-2 and alpha interferon in patients with advanced cancer: a National Biotherapy Study Group Trial.

1992 • 34 citations

Clinical experience with the combined use of recombinant interleukin‐2 (IL2) and interferon alfa‐2a (IFNα) in metastatic melanoma

1991 • 34 citations

A Phase II Trial of Concomitant Human Interleukin-2 and Interferon-??-2a in Patients with Disseminated Malignant Melanoma

1993 • 29 citations

Interleukin-2 and Interferon-??-2a Outpatient Therapy for Metastatic Renal Cell Carcinoma

1993 • 29 citations

Interleukin-2 in Combination with Interferon-Alpha in Disseminated Malignant Melanoma and Advanced Renal Cell Carcinoma

1990 • 27 citations

The out-patient use of recombinant human interleukin-2 and interferon alfa-2b in advanced malignancies

1991 • 24 citations

Immunological and clinical effects of intramuscular rlFNα-2a and low dose subcutaneous rlL-2 in patients with advanced malignant melanoma

1993 • 22 citations

Continuous intravenous interleukin-2 infusion and subcutaneous interferon-α in metastatic renal cell carcinoma

1993 • 19 citations

Phase I study of cancer therapy with recombinant interleukin-2 administered by intravenous bolus injection

1989 • 16 citations